» Articles » PMID: 36383528

Machine Learning Based Multi-modal Prediction of Future Decline Toward Alzheimer's Disease: An Empirical Study

Overview
Journal PLoS One
Date 2022 Nov 16
PMID 36383528
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a neurodegenerative condition that progresses over decades. Early detection of individuals at high risk of future progression toward AD is likely to be of critical significance for the successful treatment and/or prevention of this devastating disease. In this paper, we present an empirical study to characterize how predictable an individual subjects' future AD trajectory is, several years in advance, based on rich multi-modal data, and using modern deep learning methods. Crucially, the machine learning strategy we propose can handle different future time horizons and can be trained with heterogeneous data that exhibit missingness and non-uniform follow-up visit times. Our experiments demonstrate that our strategy yields predictions that are more accurate than a model trained on a single time horizon (e.g. 3 years), which is common practice in prior literature. We also provide a comparison between linear and nonlinear models, verifying the well-established insight that the latter can offer a boost in performance. Our results also confirm that predicting future decline for cognitively normal (CN) individuals is more challenging than for individuals with mild cognitive impairment (MCI). Intriguingly, however, we discover that prediction accuracy decreases with increasing time horizon for CN subjects, but the trend is in the opposite direction for MCI subjects. Additionally, we quantify the contribution of different data types in prediction, which yields novel insights into the utility of different biomarkers. We find that molecular biomarkers are not as helpful for CN individuals as they are for MCI individuals, whereas magnetic resonance imaging biomarkers (hippocampus volume, specifically) offer a significant boost in prediction accuracy for CN individuals. Finally, we show how our model's prediction reveals the evolution of individual-level progression risk over a five-year time horizon. Our code is available at https://github.com/batuhankmkaraman/mlbasedad.

Citing Articles

Multimodal Alzheimer's disease classification through ensemble deep random vector functional link neural network.

Henriquez P, Araya N PeerJ Comput Sci. 2025; 10:e2590.

PMID: 39896355 PMC: 11784893. DOI: 10.7717/peerj-cs.2590.


Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease.

Huang Y, Tsai T, Shen Z, Chan Y, Tu C, Tung C Alzheimers Res Ther. 2025; 17(1):3.

PMID: 39754267 PMC: 11697870. DOI: 10.1186/s13195-024-01651-0.


A Framework for Interpretability in Machine Learning for Medical Imaging.

Wang A, Karaman B, Kim H, Rosenthal J, Saluja R, Young S IEEE Access. 2024; 12:53277-53292.

PMID: 39421804 PMC: 11486155. DOI: 10.1109/access.2024.3387702.


Frontiers and hotspots evolution in mild cognitive impairment: a bibliometric analysis of from 2013 to 2023.

He C, Hu X, Wang M, Yin X, Zhan M, Li Y Front Neurosci. 2024; 18:1352129.

PMID: 39221008 PMC: 11361971. DOI: 10.3389/fnins.2024.1352129.


Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals.

Moradi E, Prakash M, Hall A, Solomon A, Strange B, Tohka J Alzheimers Res Ther. 2024; 16(1):46.

PMID: 38414035 PMC: 10900722. DOI: 10.1186/s13195-024-01415-w.


References
1.
Rosenberg P, Mielke M, Appleby B, Oh E, Geda Y, Lyketsos C . The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013; 21(7):685-95. PMC: 3428504. DOI: 10.1016/j.jagp.2013.01.006. View

2.
Jack Jr C, Barnes J, Bernstein M, Borowski B, Brewer J, Clegg S . Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement. 2015; 11(7):740-56. PMC: 4523217. DOI: 10.1016/j.jalz.2015.05.002. View

3.
Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R . Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage. 2005; 30(2):436-43. DOI: 10.1016/j.neuroimage.2005.09.046. View

4.
Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B . Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2004; 51(2):336-45. DOI: 10.1373/clinchem.2004.039347. View

5.
Mueller S, Weiner M, Thal L, Petersen R, Jack C, Jagust W . Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2007; 1(1):55-66. PMC: 1864941. DOI: 10.1016/j.jalz.2005.06.003. View